LONDON (Alliance News) - Motif Bio PLC said Tuesday that results from two clinical studies of its antibiotic iclaprim were presented at the Infectious Disease Week conference in San Diego, California, last week.
Iclaprim is currently in two phase III clinical trials for the treatment of acute bacterial skin and skin structure infections.
"Data from these studies provides us with further confidence that iclaprim can perform well in the two Phase III trials in ABSSSI," said Chief Medical Officer David Huang in a statement.
"Furthermore, the Phase II data in nosocomial pneumonia caused by Gram-positive bacteria, which are commonly identified as Staphylococcus aureus, including MRSA, provides good evidence that iclaprim may also be successful in our planned Phase III clinical trials to treat hospital-acquired and ventilator-associated bacterial pneumonia," Huang added.
Shares in Motif Bio were up 3.0% at 60.00 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.